Circulating levels of the anti-angiogenic thrombospondin 2 are elevated in pre-eclampsia

Acta Obstetricia et Gynecologica Scandinavica

Volumn 90, Issue 11, 2011, Pages 1291-1295

  Stenczer, Balázs ^a   Molvarec, Attila ^a   Veresh, Zoltán ^a   Gullai, Nóra ^a   Nagy, Gyula Richárd ^a   Walentin, Szilvia ^b   SzijártÓ, János ^a   Rigó Jr , János ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Angiogenesis inhibitor; placental growth factor; pre eclampsia; pregnancy; soluble vascular endothelial growth factor receptor 1; thrombospondin 2

Indexed keywords

PLACENTAL GROWTH FACTOR; THROMBOSPONDIN 2; VASCULOTROPIN RECEPTOR 1;

ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; THROMBOSPONDINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 80054726939     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2011.01220.x     Document Type: Article

References (21)

1. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al,. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350: 672-83. (Pubitemid 38364626)
2. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigó J Jr,. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res. 2010; 33: 892-8.
3. Bornstein P, Armstrong LC, Hankenson KD, Kyriakides TR, Yang Z,. Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol. 2000; 19: 557-68.
4. Adolph KW,. Relative abundance of thrombospondin 2 and thrombospondin 3 mRNAs in human tissues. Biochem Biophys Res Commun. 1999; 258: 792-6. (Pubitemid 29290349)
5. Lin TN, Kim GM, Chen JJ, Cheung WM, He YY, Hsu CY,. Differential regulation of thrombospondin-1 and thrombospondin-2 after focal cerebral ischemia/reperfusion. Stroke. 2003; 34: 177-86. (Pubitemid 36070819)
6. Szasz T, Eddy S, Paulauskis J, Burnett R, Ellekilde M, Iovanna JL, et al,. Differential expression of pancreatitis-associated protein and thrombospondins in arterial versus venous tissues. J Vasc Res. 2009; 46: 551-60.
7. Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM,. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol. 2004; 165: 2087-98. (Pubitemid 39578386)
8. Kyriakides TR, Rojnuckarin P, Reidy MA, Hankenson KD, Papayannopoulou T, Kaushansky K, et al,. Megakaryocytes require thrombospondin-2 for normal platelet formation and function. Blood 2003; 101: 3915-23. (Pubitemid 36857867)
9. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG,. Thrombospondins and tumor angiogenesis. Trends Mol Med. 2001; 7: 401-7. (Pubitemid 32823989)
10. Adams JC, Lawler J,. The thrombospondins. Int J Biochem Cell Biol. 2004; 36: 961-8. (Pubitemid 38528716)
11. Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF, et al,. Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun. 1995; 217: 326-32. (Pubitemid 26006308)
12. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, et al,. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A. 1999; 96: 14888-93. (Pubitemid 30019735)
13. Tomii Y, Kamochi J, Yamazaki H, Sawa N, Tokunaga T, Ohnishi Y, et al,. Human thrombospondin 2 inhibits proliferation of microvascular endothelial cells. Int J Oncol. 2002; 20: 339-42.
14. Daniel C, Amann K, Hohenstein B, Bornstein P, Hugo C,. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in experimental glomerulonephritis in mice. J Am Soc Nephrol. 2007; 18: 788-98. (Pubitemid 46434496)
15. Joubert K,. Standards of the body mass and body length of birth in Hungary on the basis of the 1990-1996 nation-wide liveborn data. Magy Noorv Lap. 2000; 63: 155-63.
16. Noh YH, Matsuda K, Hong YK, Kunstfeld R, Riccardi L, Koch M, et al,. An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. J Invest Dermatol. 2003; 121: 1536-43. (Pubitemid 38005510)
17. Simantov R, Febbraio M, Silverstein RL,. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol. 2005; 24: 27-34. (Pubitemid 40320896)
18. Panetti TS, Chen H, Misenheimer TM, Getzler SB, Mosher DF,. Endothelial cell mitogenesis induced by LPA: inhibition by thrombospondin-1 and thrombospondin-2. J Lab Clin Med. 1997; 129: 208-16. (Pubitemid 27134066)
19. Koch M, Hussein F, Woeste A, Gründker C, Frontzek K, Emons G, et al,. CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Res Treat. 2011; 128: 337-46.
20. Armstrong LC, Björkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P,. Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell. 2002; 13: 1893-905. (Pubitemid 34651480)
21. Daniel C, Wagner A, Hohenstein B, Hugo C,. Thrombospondin-2 therapy ameliorates experimental glomerulonephritis via inhibition of cell proliferation, inflammation, and TGF-β activation. Am J Physiol Renal Physiol. 2009; 297: F1299-309.